Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 332

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Lo-Coco, Francesco, Avvisati, Giuseppe, Vignetti, Marco, Breccia, Massimo, Gallo, Eugenio, Rambaldi, Alessandro, Paoloni, Francesca, Fioritoni, Giuseppe, Ferrara, Felicetto, Specchia, Giorgina, Cimino, Giuseppe, Diverio, Daniela, Borlenghi, Erika, Martinelli, Giovanni, Di Raimondo, Francesco, Di Bona, Eros, Fazi, Paola, Peta, Antonio, Bosi, Alberto, Carella, Angelo M., Fabbiano, Francesco, Pogliani, Enrico M., Petti, Maria C., Amadori, Sergio, Mandelli, Franco, for the Italian GIMEMA Cooperative Group·2010·Blood

Abstract

After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving all-trans retinoic and idarubicin (AIDA)–like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. Patients with low/intermediate risk received remission at 3 anthracycline-based consolidation courses, whereas high-risk patients received the same schedule as in the previous, non–risk-adapted AIDA-0493 trial including cytarabine. In addition, all patients in the AIDA-2000 received all-trans retinoic acid (ATRA) for 15 days during each consolidation. After induction, 600 of 636 (94.3%) and 420 of 445 (94.4%) patients achieved complete remission in the AIDA-0493 and AIDA-2000, respectively. The 6-year overall survival and cumulative incidence of relapse (CIR) rates were 78.1% versus 87.4% (P = .001) and 27.7% versus 10.7% (P < .0001). Significantly lower CIR rates for patients in the AIDA-2000 were most evident in the high-risk group (49.7% vs 9.3%, respectively, P < .0001). Our data confirm that anthracycline-based consolidation is at least equally effective as cytarabine-containing regimens for low-/intermediate-risk patients and suggest that a risk-adapted strategy including ATRA for consolidation improves outcome in newly diagnosed APL. Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group. This trial was registered at www.clinicaltrials.gov as #NCT 001064570.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-03-276196

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 332

Metadata

Authors
Lo-Coco, F., Avvisati, G., Vignetti, M., Breccia, M., Gallo, E., Rambaldi, A., Paoloni, F., Fioritoni, G., Ferrara, F., Specchia, G., Cimino, G., Diverio, D., Borlenghi, E., Martinelli, G., Di Raimondo, F., Di Bona, E., Fazi, P., Peta, A., Bosi, A., Carella, A. M., Fabbiano, F., Pogliani, E. M., Petti, M. C., Amadori, S., Mandelli, F., & for the Italian GIMEMA Cooperative Group
Venue
Blood
Published
2010-10-28
Volume
116
Issue
17
Pages
3171-3179
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2080533166
Cited by
332
References
16
FWCI
10.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. https://app.cochat.ai/papers/10.1182/blood-2010-03-276196
The paper
Lo-Coco, F., Avvisati, G., Vignetti, M., Breccia, M., Gallo, E., Rambaldi, A., Paoloni, F., Fioritoni, G., Ferrara, F., Specchia, G., Cimino, G., Diverio, D., Borlenghi, E., Martinelli, G., Di Raimondo, F., Di Bona, E., Fazi, P., Peta, A., Bosi, A., . . . for the Italian GIMEMA Cooperative Group. (2010). Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. https://doi.org/10.1182/blood-2010-03-276196

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.